Last reviewed · How we verify
CIT-013 medium dose
CIT-013 is a medium dose of a drug that targets a specific molecular pathway.
CIT-013 is a medium dose of a drug that targets a specific molecular pathway. Used for Phase 2 clinical trial for unspecified indication.
At a glance
| Generic name | CIT-013 medium dose |
|---|---|
| Sponsor | Citryll BV |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
Unfortunately, I do not have enough information to provide a deeper explanation of the mechanism of CIT-013.
Approved indications
- Phase 2 clinical trial for unspecified indication
Common side effects
- Unknown
Key clinical trials
- A Study With CIT-013 in RA Patients (PHASE2)
- A Study With CIT-013 in HS Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |